Deborah Stephens   (DO)

Deborah Stephens, DO is the Director of the Chronic Lymphocytic Leukemia (CLL)/Lymphoma Program at the Huntsman Cancer Institute at the University of Utah. She completed her internal medicine residency at Cleveland Clinic and fellowship training at The Ohio State University. Dr. Stephens leads a subspecialty clinic with a focus on patients with CLL and lymphoma. Her primary research interests include developing new targeted therapies for patients with CLL and lymphoma, studying resistance to current therapies, and developing supportive therapies for complications of CLL. She is the Physician Leader of the Hematology Clinical Trials Division at Huntsman Cancer Institute and is the principal investigator on multiple clinical trials including the international principal investigator for the SWOG S1925 EVOLVE CLL Study (NCT04269902). She is an expert panelist for the National Comprehensive Cancer Network (NCCN) CLL Guidelines Panel, which establishes and published the most widely referenced guidelines for the evaluation and treatment of patients with CLL. Dr. Stephens is also a member of the medical board for the CLL Society, which is the largest patient-led CLL group in the country. The sum of Dr. Stephens's experiences demonstrates her deep commitment to improve the care of patients with CLL and lymphoma.

Disclosure

Financial relationships Attribution: Self Type of financial relationship: Independent contractor Ineligible company: Karyopharm Date added: 09/22/2021 Date updated: 04/07/2023 Relationship end date: 04/30/2020 Attribution: Self Type of financial relationship: Independent contractor Ineligible company: Innate Pharma Date added: 09/22/2021 Date updated: 04/07/2023 Relationship end date: 01/27/2021 Attribution: Self Type of financial relationship: Independent contractor Ineligible company: Beigene Date added: 09/22/2021 Date updated: 04/07/2023 Relationship end date: 06/30/2020 Attribution: Self Type of financial relationship: Independent contractor Ineligible company: Epizyme Date added: 09/22/2021 Date updated: 04/07/2023 Relationship end date: 10/20/2020 Attribution: Self Type of financial relationship: Independent contractor Ineligible company: TG Therapeutics Date added: 09/22/2021 Date updated: 04/07/2023 Relationship end date: 02/03/2021 Attribution: Self Type of financial relationship: Independent contractor Ineligible company: Adaptive Date added: 09/22/2021 Date updated: 04/07/2023 Relationship end date: 12/20/2020 Attribution: Self Type of financial relationship: Independent contractor Ineligible company: AstraZeneca Date added: 09/22/2021 Date updated: 04/07/2023 Relationship end date: 05/13/2021 Attribution: Self Type of financial relationship: Independent contractor Ineligible company: Abbvie Date added: 09/22/2021 Date updated: 04/07/2023 Relationship end date: 06/29/2021 Attribution: Self Type of financial relationship: Independent contractor Ineligible company: CSL Behring Date added: 09/22/2021 Date updated: 04/07/2023 Relationship end date: 06/15/2021 Attribution: Self Type of financial relationship: Independent contractor Ineligible company: Celegene Date added: 09/22/2021 Date updated: 04/07/2023 Relationship end date: 06/25/2021 Type of financial relationship: Grant Or Contract Ineligible company: Karyopharm, Novartis, Arqule, Mingsight, JUNO, Newave Topic: clinical research funding Date added: 09/22/2021 Date updated: 04/07/2023